Life Molecular Imaging – Website

Innovative PET imaging agents for earlier and improved diagnosis and better characterization of diseases

Search Icon

Menu Toggle Icon

Skip to content
  • Home
  • About us
    • Leadership Team
    • Partners
    • Business Development & Licensing
    • Compliance & Code of Conduct
    • Contacts
  • Molecular Imaging
    • How It Works
    • Value of Molecular Imaging
  • Research & Development
    • Neuro-Imaging
    • Onco-Imaging
    • Cardiovascular-Imaging
  • Products
  • News
    • Current News
    • Careers

Life Molecular Imaging started recruitment for longitudinal Phase 2 Study with the Tau tracer PI-2620

17. Sep 201913. Oct 2019lifemolecular

Click to read more: The new study will thoroughly assess the accumulation and spread of Tau depositions in patients with Alzheimer’s disease and in subjects with mild cognitive impairment as visualized by PI-2620 brain uptake

Teilen mit:

  • Twitter
  • Facebook

Like this:

Like Loading...

Related

Post navigation

← DuChemBio Co. Ltd. and Life Molecular Imaging SA sign a Manufacturing and Supply Agreement for Alzheimer’s Disease Diagnostic Radiopharmaceutical for The Philippines
Life Molecular Imaging announces presentation of new research results at the European Association of Nuclear Medicine 2019 Annual Meeting →
© Copyright 2018 Life Molecular Imaging
Imprint / Data protection
Contact
Scroll to Top
Data Protection & Cookies. Our site uses cookies.
Click here to learn more: Data protection
%d bloggers like this: